¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"professional activity study"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • pressure-perfusion study
    ¾Ð·Â°ü·ù°Ë»ç
  • prospective study
    °èȹ¿¬±¸, ÀüÇ⿬±¸, ¾Õ¹æÇ⿬±¸
  • real time study
    ½Ç½Ã°£°Ë»ç
  • retrospective study
    ÈÄÇ⿬±¸, µÞ¹æÇ⿬±¸
  • study
    ¿¬±¸, °Ë»ç
  • single blind study
    ´ÜÀϸͰ˹ý
  • survivorship study
    »ýÁ¸¿¬±¸
  • time study
    ½Ã°£¿¬±¸
  • tracer study
    ÃßÀûÀÚ¿¬±¸
  • urodynamic study
    ¿ä¿ªµ¿Çа˻ç
  • video-urodynamic study
    ¿µ»ó¿ä¿ªµ¿Çа˻ç
  • water-loading study
    ¼öºÐºÎÇÏ¿¬±¸
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • functional activity
    ±â´É¼º Ȱ¼ºµµ<Ȱµ¿µµ>
  • fusion activity
    À¶ÇÕ´É
  • glucagon activity
    ±Û·çÄ«°ïȰ¼ºµµ.
  • helper cell activity
    Á¶·Â¼¼Æ÷´É, º¸Á¶¼¼Æ÷´É
  • hemolytic activity
    ¿ëÇ÷´É
  • homosexual activity
    µ¿¼º¾ÖÀû ÇàÀ§
  • insulin like activity =ILa
    Àν¶¸°¾çȰ¼º(ÀÛ¿ë).
  • insulin-like activity substance
    Àν¶¸°¾çȰ¼º¹°Áú.
  • intrinsic activity
    ¾à¸®³»ÀÎ<Àç>¼º Ȱ¼º.
  • intrinsic activity
    ³»È°¼º(Ò®üÀàõ).[¾à¸®]³»ÀÎ<Àç>¼º Ȱ¼º.
  • intrinsic sympathomimetic activity
    ³»Àμº ±³°¨½Å°æÀ¯»çÀÛ¿ë.
  • intrinsic sympathomimetic activity
    ³»Àμº ±³°¨½Å°æÀÚ±ØÀÛ¿ë.[¾à¸®]³» ÀÎ<Àç>¼º ±³°¨½Å°æÀ¯»çȰ¼º.
  • laboratory activity
    °Ë»ç½ÇȰµ¿
  • lipase activity
    ¸®ÆÄÁ¦ Ȱ¼ºµµ
  • lipolytic activity
    ÁöÁúºÐÇØÀûÇØ.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
TGA taurocholate gelatin agar; thyroglobulin activity; total glycoalkaloids; total gonadotropin activity...
ABEPP American Board of Examiners in Professional Psychology
CPHA Canadian Public Health Association; Commission on Professional and Hospital Activities
CPHQ certified professional in healthcare quality
CPQA certified professional in quality assurance
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
CHS Cardiovascular Health Study
CCSG Childrens Cancer Study Group
CLAS Cholesterol Lowering Atherosclerosis Study
CBTS Collaborative Behavioral Teratology Study
COMS Collaborative Ocular Melanoma Study
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • serum diastase activity
    Ç÷û µð¾Æ½ºÅ¸Á¦Ä¡
    Ç÷û¿¡ ÇÔÀ¯µÈ ¾Æ¹Ð¶ó¾ÆÁ¦ÀÇ ¾çÀ» ³ªÅ¸³»´Âµ¥ »ç¿ëÇÑ´Ù.
  • social welfare activity
    »çȸ º¹Áö»ç¾÷
  • specific activity
    ƯÀÌ È°¼º, ƯÀÌ È°¼ºµµ, ºñȰ¼º, ºñȰ¼ºµµ
  • spontaneous activity
    ÀÚ¹ßÀû Ȱµ¿
  • sympathetic efferent activity
    ¿ø½É¼º ±³°¨½Å°æ Ȱµ¿, ¿ø½É¼º ±³°¨½Å°æ Ȱ¼º
  • sympathetic nervous system activity
    ±³°¨½Å°æ°è Ȱ¼º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 5
study, longitudinal A study done over the passage of time. For example, a longitudinal study of children with down syndrome (trisomy 21) might involve the study of 100 children with this condition from birth to 10 years of age. Also called a diachronic study. The opposite of a cross-sectional (synchronic) study.
(12 Dec 1998)
study, preclinical A study to test a drug, procedure or medical treatment in animals. The aim is to collect data in support of safety. Preclinical studies are required before clinical trials can be started.
(12 Dec 1998)
study, synchronic See: Study, cross-sectional.
(12 Dec 1998)
synchronic study <epidemiology> A study in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with longitudinal studies which are followed over a period of time.
Synonym: horizontal study.
(18 Jul 2002)
diachronic study A study done over the course of time. For example, a longitudinal study of children with Down syndrome (trisomy 21) might involve the study of 100 children with this condition from birth to 10 years of age. Also called a longitudinal study. The opposite of a synchronic (cross-sectional) study.
(12 Dec 1998)
double-blind study A study in which neither the experimenter nor any other assessor of the results, including patients, know which group is subject to which procedure, thus helping assure that the biases or expectations of either will not influence the results.
(05 Mar 2000)
epidemiologic study characteristics Types and formulations of studies used in epidemiological and clinical research.
(12 Dec 1998)
twin study A method of detecting genetic causes in human traits and genetic factors in behaviour using sets of twins.
(12 Dec 1998)
foetal doppler study <radiology> Non-stress test (NST), external monitoring for 20 minutes; poor specificity, greater than4 foetal heart accelerations (greater than15 bpm over baseline for 15 seconds) following foetal movement in foetus greater than34 weeks, no heart accelerations in immaturity, sleep, maternal sedation contraction stress test (CST), external monitoring after oxytocin or maternal breast stimulation, greater than 3 uterine contraction in 10 minutes; 50% specificity uterine and umbilical artery waveform, elevated systolic:diastolic ratio = increased vascular resistance foetal aortic flow volume, 185-246 ml/kg/min see also: biophysical profile, intrauterine growth retardation (IUGR)
(12 Dec 1998)
follow-up study Study in which persons exposed to risk or given a designated preventive or therapeutic regimen are observed over a period or at intervals to determine the outcome of the exposure or regimen.
(05 Mar 2000)
Framingham Heart study <epidemiology> Ongoing epidemiologic study of a cohort of over 5,000 of the population of Framingham, MA conducted since 1949 under the auspices of the National Institutes of Health and Boston University.
(05 Mar 2000)
longitudinal study <epidemiology> A study taking place over time. If individuals are followed, this is a longitudinal cohort study. If individuals are not followed, but classes (usually age classes) are restudied, this is a longitudinal cross-sectional study.
The converse of a horizontal study.
(05 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á